AAAAAA

   
Results: 1-18 |
Results: 18
Bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone (BLEO-CCVPP) in patients with Hodgkin's disease who relapsed after radiotherapy alone: A long-term follow-up study of the Eastern Cooperative Oncology Group (E3481)
Authors: Wiernik, PH Leong, T Oken, MM Neiman, RS Habermann, TM Bennett, JM Schuster, S Glick, JH
Citation: Ph. Wiernik et al., Bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone (BLEO-CCVPP) in patients with Hodgkin's disease who relapsed after radiotherapy alone: A long-term follow-up study of the Eastern Cooperative Oncology Group (E3481), LEUK LYMPH, 40(3-4), 2001, pp. 357-363
Combined modality treatment for locally advanced squamous-cell carcinoma of the oropharynx in a woman with Bloom's syndrome: A case report and reviewof the literature
Authors: Ma, B Corry, J Rischin, D Leong, T Peters, LJ
Citation: B. Ma et al., Combined modality treatment for locally advanced squamous-cell carcinoma of the oropharynx in a woman with Bloom's syndrome: A case report and reviewof the literature, ANN ONCOL, 12(7), 2001, pp. 1015-1017
Phase III comparison of high-dose paclitaxel plus cisplatin plus granulocyte colony-stimulating factor versus low-dose paclitaxel plus cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393
Authors: Forastiere, AA Leong, T Rowinsky, E Murphy, BA Vlock, DR DeConti, RC Adams, GL
Citation: Aa. Forastiere et al., Phase III comparison of high-dose paclitaxel plus cisplatin plus granulocyte colony-stimulating factor versus low-dose paclitaxel plus cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393, J CL ONCOL, 19(4), 2001, pp. 1088-1095
Novel DNA sequence variants in the hHR21 DNA repair gene in radiosensitivecancer patients
Authors: Severin, DM Leong, T Cassidy, B Elsaleh, H Peters, L Venter, D Southey, M McKay, M
Citation: Dm. Severin et al., Novel DNA sequence variants in the hHR21 DNA repair gene in radiosensitivecancer patients, INT J RAD O, 50(5), 2001, pp. 1323-1331
Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial
Authors: Herbst, RS Lynch, C Vasconcelles, M Teicher, BA Strauss, G Elias, A Anderson, I Zacarola, P Dang, NH Leong, T Salgia, R Skarin, AT
Citation: Rs. Herbst et al., Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial, CANC CHEMOT, 48(2), 2001, pp. 151-159
Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck - An Eastern Cooperative Oncology Group trial (E3393)
Authors: Murphy, BA Leong, T Burkey, B Langer, C Forastiere, A
Citation: Ba. Murphy et al., Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck - An Eastern Cooperative Oncology Group trial (E3393), AM J CL ONC, 24(1), 2001, pp. 64-66
Incomplete covariates in the Cox model with applications to biological marker data
Authors: Leong, T Lipsitz, SR Ibrahim, JG
Citation: T. Leong et al., Incomplete covariates in the Cox model with applications to biological marker data, J ROY STA C, 50, 2001, pp. 467-484
Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients
Authors: Casassus, P Gibson, J Joshua, DE Matthews, J Diaz, JC Gertz, MA Kyle, R Leong, T Oken, MM Fritz, E Ludwig, H Corrado, C Lastiri, F Peest, D Grosbois, B Vela-Ojeda, J Avvisati, G Mandelli, F Petrucci, MT Capnist, G Child, JA Drayson, MT Dunn, J MacLennan, I Mellstedt, H Osterborg, A Rodjer, S Turesson, I Westin, J Bergsagel, D Browman, GP Shustik, C Zee, B Hjorth, M Holmberg, E Rodjer, S Turesson, I Westin, J Alison, R Clarke, M Elphinstone, P Evans, V Gray, R Hicks, C James, S MacKinnon, L Peto, R Richards, S Wheatley, K Blade, J Fontanillas, M San Miguel, J Aitchison, R Newland, AC Cunningham, D Malpas, J Powles, RL Montuoro, A Jacobson, J Salmon, S
Citation: P. Casassus et al., Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients, BR J HAEM, 113(4), 2001, pp. 1020-1034
Prognostic value of bone marrow angiogenesis in multiple myeloma
Authors: Rajkumar, SV Leong, T Roche, PC Fonseca, R Dispenzieri, A Lacy, MQ Lust, JA Witzig, TE Kyle, RA Gertz, MA Greipp, PR
Citation: Sv. Rajkumar et al., Prognostic value of bone marrow angiogenesis in multiple myeloma, CLIN CANC R, 6(8), 2000, pp. 3111-3116
Mutation analysis of BRCA1 and BRCA2 cancer predisposition genes in radiation hypersensitive cancer patients
Authors: Leong, T Whitty, J Keilar, M Mifsud, S Ramsay, J Birrell, G Venter, D Southey, M McKay, M
Citation: T. Leong et al., Mutation analysis of BRCA1 and BRCA2 cancer predisposition genes in radiation hypersensitive cancer patients, INT J RAD O, 48(4), 2000, pp. 959-965
Prognostic value of serum markers of bone metabolism in untreated multiplemyeloma patients
Authors: Fonseca, R Trendle, MC Leong, T Kyle, RA Oken, MM Kay, NE Van Ness, B Greipp, PR
Citation: R. Fonseca et al., Prognostic value of serum markers of bone metabolism in untreated multiplemyeloma patients, BR J HAEM, 109(1), 2000, pp. 24-29
Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma?
Authors: Greipp, PR Trendle, MC Leong, T Oken, MM Kay, NE Van Ness, B Kyle, RA
Citation: Pr. Greipp et al., Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma?, LEUK LYMPH, 35(1-2), 1999, pp. 83-89
Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myelomapatients, a study of the Eastern Cooperative Oncology Group (E9487)
Authors: Kay, N Leong, T Kyle, RA Greipp, P Van Ness, B Bone, N Oken, MM
Citation: N. Kay et al., Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myelomapatients, a study of the Eastern Cooperative Oncology Group (E9487), LEUK LYMPH, 33(1-2), 1999, pp. 127-133
Prognostic significance of the S-phase fraction of light-chain-restricted cytoplasmic immunoglobulin (clg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on Eastern Cooperative Oncology Group treatment trial E9486
Authors: Trendle, MC Leong, T Kyle, RA Katzmann, JA Oken, MM Kay, NE Van Ness, BG Greipp, PR
Citation: Mc. Trendle et al., Prognostic significance of the S-phase fraction of light-chain-restricted cytoplasmic immunoglobulin (clg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on Eastern Cooperative Oncology Group treatment trial E9486, AM J HEMAT, 61(4), 1999, pp. 232-237
Using missing data methods in genetic studies with missing mutation status
Authors: Leong, T Lipsitz, SR Ibrahim, JG
Citation: T. Leong et al., Using missing data methods in genetic studies with missing mutation status, STAT MED, 18(4), 1999, pp. 473-485
The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma - Phase III Eastern Cooperative Oncology Group clinical trial EST 9486
Authors: Oken, MM Leong, T Lenhard, RE Greipp, PR Kay, NE Van Ness, B Keimowitz, RM Kyle, RA
Citation: Mm. Oken et al., The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma - Phase III Eastern Cooperative Oncology Group clinical trial EST 9486, CANCER, 86(6), 1999, pp. 957-968
Combination chemotherapy versus melphalan plus prednisone as treatment formultiple myeloma: An overview of 6,633 patients from 27 randomized trials
Authors: Pasquali, S Maqueo, JD Vela, J Kyle, RA Leong, T Fritz, E Suciu, S Palva, IP Oivanen, T Corrado, C Lastiri, FJ Peest, D Kildahl-Andersen, O Maniatis, A Alison, R Clarke, M Evans, V Gray, R Greaves, E Hall, E Hicks, C James, S Peto, R Richards, S Sinclair, D Tooth, A Wheatley, K Avvisati, G Boccadoro, M Bugliosi, R Mandelli, F Petrucci, MT Pileri, A Tribalto, M Alexanian, R Delasalle, KB Child, J Dunn, J MacLennan, I Milligan, D Mellstedt, H Osterborg, A Hjorth, M Holmberg, E Rodjer, S Westin, J Kamiya, O Shimizu, K Bergsagel, DE Shustik, C Hippe, E Kjaersgaard, E Turesson, I Westin, J Riccardi, A Ucci, G Blade, J Fontanillas, M De Rosa, L Montuoro, A Bartolucci, AA Omura, GA Stagg, M Salmon, S Tangen, C Jacobs, P Wood, L Levy, LM
Citation: S. Pasquali et al., Combination chemotherapy versus melphalan plus prednisone as treatment formultiple myeloma: An overview of 6,633 patients from 27 randomized trials, J CL ONCOL, 16(12), 1998, pp. 3832-3842
Paclitaxel as the initial treatment of multiple myeloma - An Eastern Cooperative Oncology Group Study (E1A93)
Authors: Miller, HJ Leong, T Khandekar, JD Greipp, PR Gertz, MA Kyle, RA
Citation: Hj. Miller et al., Paclitaxel as the initial treatment of multiple myeloma - An Eastern Cooperative Oncology Group Study (E1A93), AM J CL ONC, 21(6), 1998, pp. 553-556
Risultati: 1-18 |